

Date of report 18 Dec 2023

# Reported case interaction between Bictegravir and Oxcarbazepine

## Drugs suspected to be involved in the DDI

Victim

**Bictegravir** 

Dose adjustment performed

No

Start date

March 31, 2021

Daily Dose

50 (mg)

Administration Route

Oral

End date

**Ongoing** 

Perpetrator

Oxcarbazepine

Dose adjustment performed

No

Start date

June 1, 2013

Daily Dose

600 (mg)

Administration Route

Oral

End date

June 1, 2022

## Complete list of drugs taken by the patient

Antiretroviral treatment

Bictegravir/Emtricitabine/Tenofovir-AF

Complete list of all comedications taken by the patient, included that involved in the DDI

Oxcarbazepine, Mirtazapine, Fluoxetine, Enalapril/HCZ, Omeprazole

## **Clinical case description**

Gender Age Female 66

eGFR (mL/min) Liver function impairment

>60 No

#### Description

This is a clinical case describing some DDIs between ARV (BIC, b/DRV and MVC) and oxcabrazepine as concomitant drug.

Female, 67 years old with HIV infection diagnosed in 1999. Undetectable viral load fron March 2014 to present. The patient had received the following ARV regimens:

- DRV/r 800/100mg + MVC 300mg QD (from 27/12/2013 to 21/06/2016), due to viral failure and M184V and K103N mutations emergence with EFV/FTC/TDF.
- DRV/c 800/150mg + MVC 300mg QD (from 21/06/2016 to 31/03/2021), a a simplification strategy to reduce the number of pills.
- BIC/FTC/TAF (from 31/02/2021 and ongoing), to simplify to a STR and to improve lipid profile, as the patient had developed hypercholesterolemia that required statins.

The patient had been taking oxcarbazepine (always same dose, 300mg/12h) since June 2013 due to a long history of alcohol abuse and in order to control withdrawal syndrome, as well as, long-time depression. Oxcarbazepine was stopped by Psychiatrist in June 2022, due to a mild hyponatremia, and it was changed to Quetiapine and Pregabalin.

#### **Clinical Outcome**

#### No unwanted outcome

### **Editorial Comment**

Oxcarbazepine may induce CYP3A, UGT1A1, and P-gp, potentially decreasing plasma concentrations of different antiretroviral drugs, including darunavir, bictegravir and tenofovir alafenamide, which may result in loss of therapeutic effect and development of resistance. Therefore, co-administration is not recommended, and alternative anticonvulsants should be considered. If not possible, consider dolutegravir 50 mg BID.

In this case, despite the potential interactions no viral rebound was observed. However, a close monitoring should be recommended and, if possible, TDM might be useful.

## **University of Liverpool Recommendation**

These drugs should not be coadministered

## For more information click here

## **Personal information from the specialist**

Name Surname

Jordi Navarro

Institution Country

Hospital Vall d'Hebron ES